BACKGROUND: The Asthma Impact Survey (AIS-6) is a new six question asthma outcome tool for which information on validity has not been published. OBJECTIVE: To provide validation for the AIS-6 as a brief asthma-specific quality of life tool. METHODS: Surveys were sent to a random sample of members of a large managed care organization who were at least 35 years of age and in the two-year period preceding the survey had either (1) at least one documented asthma-related medical encounter, or (2) at least a 6 months supply of asthma medication dispensed. In addition to the AIS-6, the survey included a validated quality of life tool [the mini-Asthma Quality of Life Questionnaire (AQLQ)]; a validated asthma control questionnaire [the Asthma Therapy Assessment Questionnaire (ATAQ)]; a validated symptom severity scale (AOMS); and information regarding demographics, co-morbidities, asthma severity, and asthma management. The results of the AIS-6 were compared to the results of the other tools by means of correlation and factor analysis. Independent predictors of AIS-6 and AQLQ scores were determined by multiple stepwise linear regression analyses. RESULTS: AIS-6 scores were significantly related to female sex, educational level, income, smoking, body mass index (BMI), COPD, steroid use, and hospitalization history in bivariate analyses. The AIS-6 score significantly correlated (r = - 0.84, p < 0.0001) with the AQLQ total score and loaded on the three factors (activity, symptoms, and concern/bother) reflected by the survey information and on which the AQLQ also loaded. Significant but somewhat smaller correlations were found between the AIS-6 and the ATAQ (r = 0.70, p < 0.0001) and the AOMS (r = 0.55, p < 0.0001). Independent predictors were the same for the AIS-6 and AQLQ and included oral steroid use, COPD history, BMI, female sex, educational level, and hospitalization in the past year. CONCLUSION: These data support the validity of the short six-question AIS-6 as an asthma-specific quality of life tool.
BACKGROUND: The Asthma Impact Survey (AIS-6) is a new six question asthma outcome tool for which information on validity has not been published. OBJECTIVE: To provide validation for the AIS-6 as a brief asthma-specific quality of life tool. METHODS: Surveys were sent to a random sample of members of a large managed care organization who were at least 35 years of age and in the two-year period preceding the survey had either (1) at least one documented asthma-related medical encounter, or (2) at least a 6 months supply of asthma medication dispensed. In addition to the AIS-6, the survey included a validated quality of life tool [the mini-Asthma Quality of Life Questionnaire (AQLQ)]; a validated asthma control questionnaire [the Asthma Therapy Assessment Questionnaire (ATAQ)]; a validated symptom severity scale (AOMS); and information regarding demographics, co-morbidities, asthma severity, and asthma management. The results of the AIS-6 were compared to the results of the other tools by means of correlation and factor analysis. Independent predictors of AIS-6 and AQLQ scores were determined by multiple stepwise linear regression analyses. RESULTS: AIS-6 scores were significantly related to female sex, educational level, income, smoking, body mass index (BMI), COPD, steroid use, and hospitalization history in bivariate analyses. The AIS-6 score significantly correlated (r = - 0.84, p < 0.0001) with the AQLQ total score and loaded on the three factors (activity, symptoms, and concern/bother) reflected by the survey information and on which the AQLQ also loaded. Significant but somewhat smaller correlations were found between the AIS-6 and the ATAQ (r = 0.70, p < 0.0001) and the AOMS (r = 0.55, p < 0.0001). Independent predictors were the same for the AIS-6 and AQLQ and included oral steroid use, COPD history, BMI, female sex, educational level, and hospitalization in the past year. CONCLUSION: These data support the validity of the short six-question AIS-6 as an asthma-specific quality of life tool.
Authors: Michael Schatz; David Mosen; Andrea J Apter; Robert S Zeiger; William M Vollmer; Thomas B Stibolt; Albin Leong; Michael S Johnson; Guillermo Mendoza; E Francis Cook Journal: J Allergy Clin Immunol Date: 2005-05 Impact factor: 10.793
Authors: William M Tierney; J Franklin Roesner; Roopa Seshadri; Michael G Lykens; Michael D Murray; Morris Weinberger Journal: J Gen Intern Med Date: 2004-03 Impact factor: 5.128
Authors: Sandra R Wilson; Cynthia S Rand; Michael D Cabana; Michael B Foggs; Jill S Halterman; Lynn Olson; William M Vollmer; Rosalind J Wright; Virginia Taggart Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Cathy D Sherbourne; Brian D Stucky; Maria Orlando Edelen; Nicole K Eberhart; Eric Kleerup; Marielena Lara Journal: J Allergy Clin Immunol Date: 2014-04-18 Impact factor: 10.793
Authors: Brian D Stucky; Maria Orlando Edelen; Cathy D Sherbourne; Nicole K Eberhart; Marielena Lara Journal: Respir Med Date: 2013-12-25 Impact factor: 3.415
Authors: Nicole K Eberhart; Cathy D Sherbourne; Maria Orlando Edelen; Brian D Stucky; Nancy L Sin; Marielena Lara Journal: Qual Life Res Date: 2013-09-24 Impact factor: 4.147
Authors: Elizabeth W Holt; Earl Francis Cook; Ronina A Covar; Joseph Spahn; Anne L Fuhlbrigge Journal: J Allergy Clin Immunol Date: 2008-05 Impact factor: 10.793
Authors: Ann Chen Wu; Robert Davis; Kelan Tantisira; M Maya Dutta-Linn; Mia Hemmes; Scott T Weiss Journal: J Pharmacogenomics Pharmacoproteomics Date: 2011-04-04
Authors: Ann Chen Wu; Lingling Li; Vicki Fung; Elyse O Kharbanda; Emma K Larkin; Melissa G Butler; Alison Galbraith; Irina Miroshnik; Robert L Davis; Kelly Horan; Tracy A Lieu Journal: J Allergy Clin Immunol Pract Date: 2016-05-17